78238-13-8

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl 3-methoxy-5-nitrobenzoate is used as an intermediate in the production of various drugs for its ability to facilitate the synthesis of active pharmaceutical ingredients.
Used in Flavor and Fragrance Industry:
Ethyl 3-methoxy-5-nitrobenzoate is used as a flavor and fragrance ingredient due to its mild, sweet, and fruity odor, contributing to the creation of perfumes and other scented products.
Used in Organic Compound Synthesis:
Ethyl 3-methoxy-5-nitrobenzoate is utilized as a key component in the synthesis of organic compounds, playing a crucial role in the development of new chemical entities with potential applications in various industries.
It is important to handle ethyl 3-methoxy-5-nitrobenzoate with care, as prolonged exposure can lead to skin and eye irritation.

Upstream product

• 186581-53-3 diazomethane 
• 78238-12-7 3-methoxy-5-nitrobenzoic acid 
• 67-56-1 methanol 
• 2702-58-1 methyl 3,5-dinitrobenzoate 
• 78238-14-9 3-hydroxy-5-nitrobenzoic acid 
• 74-88-4 methyl iodide 
• 618-71-3 ethyl 3,5-dinitrobenzoate 
• 865-34-9 lithium methanolate 
• 99-34-3 3,5-dinitrobenzoic acid 
• 55076-32-9 methyl 3-hydroxy-5-nitrobenzoate 
• 77-78-1 dimethyl sulfate 

Downstream Products

• 78238-12-7 3-methoxy-5-nitrobenzoic acid 
• 78238-14-9 3-hydroxy-5-nitrobenzoic acid 
• 292635-40-6 3-methoxy-5-nitrobenzamide 
• 56709-74-1 methyl 3-bromo-2,6-dinitro-5-methoxybenzoate 
• 883554-93-6 methyl 5-bromo-2-nitro-3-methoxybenzoate 
• 78238-03-6 3-methoxy-5-acetylaminobenzoic acid 
• 78238-07-0 methyl 3-methoxy-5-acetylaminobenzoate 
• 78238-05-8 2-nitro-3-methoxy-5-aminobenzoic acid 
• 78238-06-9 methyl ester of 2-nitro-3-methoxy-5-aminobenzoic acid 
• 78238-04-7 2-nitro-3-methoxy-5-acetylaminobenzoic acid 
• 343220-53-1 3-bromo-2,6-dinitro-5-methoxybenzoic acid 
• 78238-10-5 2,6-dinitro-3-methoxy-5-aminobenzoic acid 
• 78238-08-1 2,6-dinitro-3-methoxy-5-acetylaminobenzoic acid 
• 78238-09-2 methyl 2,6-dinitro-3-methoxy-5-acetylaminobenzoate 

Relevant academic research and scientific papers

Discovery of (3-Benzyl-5-hydroxyphenyl)carbamates as new antitubercular agents with potent in vitro and in vivo efficacy

A series of 3-amino-5-benzylphenol derivatives were designed and synthesized. Among them, (3-benzyl-5-hydroxyphenyl)carbamates were found to exert good inhibitory activity against M. tuberculosis H37Ra, H37Rv and clinically isolated multidrug-resistant M. tuberculosis strains (MIC = 0.625-6.25 μg/mL). The privileged compounds 3i and 3l showed moderate cytotoxicity against cell line A549. Compound 3l also exhibited potent in vivo inhibitory activity on a mouse infection model via the oral administration. The results demonstrated 3-hydroxyphenylcarbamates as a class of new antitubercular agents with good potential.

Design, synthesis, and biological evaluation of m-amidophenol derivatives as a new class of antitubercular agents

A series of m-amidophenol derivatives (6a-6l, 7a-7q, 9a, 9b, 12a-12c, 14 and 15) were designed and synthesized. Their antitubercular activities were evaluated in vitro against M. tuberculosis strains H37Ra and H37Rv and clinically isolated multidrug-resistant M. tuberculosis strains. Ten compounds displayed minimal inhibitory concentrations (MICs) against M. tuberculosis H37Ra below 2.5 μg mL?1 and 6g was the most active compound (MIC = 0.625 μg mL?1). Compounds 6g and 7a also showed potent inhibitory activity against M. tuberculosis H37Rv (MIC = 0.39 μg mL?1) and several clinically isolated multidrug-resistant M. tuberculosis strains (MIC = 0.39-3.125 μg mL?1). The compounds did not show inhibitory activity against normal Gram-positive and Gram-negative bacteria. They exhibited low cytotoxicity against HepG2 and RAW264.7 cell lines. The results demonstrated m-amidophenol as an attractive scaffold for the development of new antitubercular agents.

Monoenomycin: A simplified trienomycin A analogue that manifests anticancer activity

Macrocyclic natural products are a powerful class of leadlike chemical entities. Despite commonly violating Lipinski's "rule of 5", these compounds often demonstrate superior druglike physicochemical and pharmacokinetic attributes when compared to their acyclic counterparts. However, the elaborate structural architectures of such molecules require rigorous synthetic investigation that complicates analogue development and their application to drug discovery programs. To circumvent these limitations, a conformation-based approach using limited structure-activity relationships and molecular modeling was implemented to design simplified analogues of trienomycin A, in which the corresponding analogues could be prepared in a succinct manner to rapidly identify essential structural components necessary for biological activity. Trienomycin A is a member of the ansamycin family of natural products that possesses potent anticancer activity. These studies revealed a novel trienomycin A analogue, monoenomycin, which manifests potent anticancer activity.

BENZAMIDE FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS

The present invention provides novel benzamide derivatives of Formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein the variables A, W, Y, Z, R8, and R9 are as defined herein. These compounds are selective inhibitors of factor VIIa which can be used as medicaments.

(3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR TREATING

The present invention provides novel beta-secretase inhibitors and methods for their use, including methods of treating of Alzheimer's disease. (Formula)

MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS

The invention relates to novel macrocyclic compounds of the Formula (I) in which all of the variables are as defined in the specification, in free base form or in acid addition salt form, to their preparation, to their use as medicaments and to medicaments comprising them.

Allosteric regulation of the conformational dynamics of a cavitand receptor

Inspired by allostery in nature, we synthesized cavitand 1 and investigated regulation of its conformational dynamics. Quantitative 1H NMR studies have revealed that the rate of the conformational isomerization of 1 can be modulated using the e

Heterogeneous foldamers containing alpha, beta, and/or gamma-amino acids

Disclosed are isolated, unnatural polypeptides containing cyclically-constrained β-amino acid residues and cyclically-constrained γ-amino acid residues. The compounds are unnatural and because they contain rotationally constrained residues that are not amenable to enzymatic degradation, the compounds are useful to probe protein-protein and other large molecule interactions.

PHTHALAZINE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS

Compounds of formula I wherein R and R1 are as defined in the description.The compounds of formula I are PDE 4 inhibitors.

ASPARTYL PROTEASE INHIBITORS

The present invention provides compounds having formula (I): wherein R’, R0, R1, X1, R2, R3, R3’, X2, X3, and R4 are as defined herein, and pharmaceuticals compositions thereof. The present invention also provides methods of inhibiting proteases, more specially aspartyl proteases. In certain embodiments, compounds inhibit BACE (β-site APP-cleaving enzyme), and thus are useful in the treatment or prevention of a disease characterized by β-amyloid deposits in the brain (including, but not limited to, Alzheimer’s Disease). The present invention also provides methods for preparing compounds of the invention.